Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients

  • Authors:
    • Elena Collovà
    • Bianca Rovati
    • Donatella Grasso
    • Katia Bencardino
    • Mariangela Manzoni
    • Marco Danova
  • View Affiliations

  • Published online on: January 1, 2009     https://doi.org/10.3892/mmr_00000066
  • Pages: 85-88
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to evaluate the effect of dose-dense adjuvant chemotherapy regimens with peg-filgrastim support on the phenotype of peripheral blood leukocytes in breast cancer patients. We evaluated the leukocyte phenotype of 14 patients aged 46-67 years undergoing 4 courses of chemotherapy with either epirubucin/cyclophosphamide (n=7) or 5-fluorouracil/epirubucin/cyclophosphamide (n=7) followed by 4 courses of taxol supported by peg-filgrastim (6 mg) administered 72 h after each chemotherapy course. The overall leukocyte number significantly increased from the first treatment course, while total lymphocytes tended to decrease with a negative peak following the 6th course (p=0.03). B (CD19+, CD20+) and early B lymphocyte subsets (CD20+/CD38+) significantly decreased during treatment (p<0.05), while T lymphocyte subsets did not show significant changes, except a decrease in T helper (CD4+) cells. Immature T lymphocytes (CD4+/CD8+ subset), dendritic cells (CD11c+) and NK cells (CD56+) increased with respect to the baseline. Our results suggest that dose-dense chemotherapy programs with the support of peg-filgrastim did not significantly impair the immune system of breast cancer patients and allowed for a rapid restoration of most immune competent cells. These observations may have important clinical implications with a view to vaccination or other immunotherapeutic approaches to solid tumours.

Related Articles

Journal Cover

January-February 2009
Volume 2 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Collovà E, Rovati B, Grasso D, Bencardino K, Manzoni M and Danova M: Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients. Mol Med Rep 2: 85-88, 2009
APA
Collovà, E., Rovati, B., Grasso, D., Bencardino, K., Manzoni, M., & Danova, M. (2009). Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients. Molecular Medicine Reports, 2, 85-88. https://doi.org/10.3892/mmr_00000066
MLA
Collovà, E., Rovati, B., Grasso, D., Bencardino, K., Manzoni, M., Danova, M."Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients". Molecular Medicine Reports 2.1 (2009): 85-88.
Chicago
Collovà, E., Rovati, B., Grasso, D., Bencardino, K., Manzoni, M., Danova, M."Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients". Molecular Medicine Reports 2, no. 1 (2009): 85-88. https://doi.org/10.3892/mmr_00000066